StockData
Sionna Therapeutics, Inc. logo

Sionna Therapeutics, Inc. (SION) stock

SIONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$2.83−0.15 (-4.88%)

Close on Nov 20, 2026Market cap $127.73MP/E –Yield –

Sionna Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Sionna Therapeutics's free cash flow for the twelve months ending Sep 30, 2026 was -$79.61M. For fiscal 2025 it was -$66.67M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$66.67M–
FY2024Dec 31, 2024-$52.81M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$18.72M–
Q2 FY2026Jun 30, 2026-$22.22M–
Q1 FY2026Mar 31, 2026-$21.84M–
Q4 FY2025Dec 31, 2025-$16.83M–
Q3 FY2025Sep 30, 2025-$15.32M–
Q2 FY2025Jun 30, 2025-$18.15M–
Q1 FY2025Mar 31, 2025-$16.37M–
Q4 FY2024Dec 31, 2024-$11.81M–
Q3 FY2024Sep 30, 2024-$17.69M–
Q2 FY2024Jun 30, 2024-$10.15M–
Q1 FY2024Mar 31, 2024-$13.18M–

More Sionna Therapeutics figures

See a number that looks wrong?